Does Teva’s Celiac Drug Breakthrough and $500 Million Backing Redefine the Bull Case For TEVA?

• Teva Pharmaceutical Industries recently reported positive topline results from a Phase 2a trial of its anti‑IL‑15 antibody TEV ‘408 in adults with celiac disease, meeting the primary endpoint of preventing gluten‑induced intestinal damage with a favorable safety profile.
• With no approved drug treatments for celiac disease today and Royalty Pharma committing US$500 million to accelerate TEV ‘408’s development, this program highlights Teva’s potential “pipeline‑in‑a‑product” opportunity beyond its traditional generics base.
• We’ll now explore how TEV ‘408’s early success in an underserved celiac market could reshape Teva’s investment narrative and long‑term growth mix.

Outshine the giants: these 19 early-stage AI stocks could fund your retirement.

Teva Pharmaceutical Industries Investment Narrative Recap

To own Teva today, you need to believe its “Pivot to Growth” can gradually offset a flat generics base with higher margin branded and specialty drugs, while the balance sheet keeps improving from still-elevated debt. The TEV ‘408 Phase 2a celiac readout looks additive rather than transformational in the near term, as the key short term catalyst remains execution on AUSTEDO, AJOVY and UZEDY growth, with pipeline and pricing risks still front of mind.

Among recent announcements, the S&P upgrade of Teva’s long term issuer rating to BBB‑, giving it investment grade status across all major agencies, feels most relevant. It reinforces that creditors view Teva’s financial profile and “Pivot to Growth” as progressing, which may support funding costs as the company invests in TEV ‘408 and other late stage assets that underpin its longer term growth mix.

Yet while TEV ‘408 offers fresh optionality, investors should still be aware of how concentrated Teva’s growth is in a handful of branded drugs and how…

Read the full narrative on Teva Pharmaceutical Industries (it’s free!)

Teva Pharmaceutical Industries’ narrative projects $18.1 billion revenue and $2.7 billion earnings by 2029. This requires 1.5% yearly revenue growth and about a $1.1 billion earnings increase from $1.6 billion today.

Uncover how Teva Pharmaceutical Industries’ forecasts yield a $40.90 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already counting on revenue near US$18.7 billion and earnings of about US$3.3 billion by 2029, so TEV ‘408’s progress and the broader “pipeline in a product” story could either support that ambitious view or remind you how much still rests on a few late stage programs and cost savings actually coming through.

Explore 4 other fair value estimates on Teva Pharmaceutical Industries – why the stock might be worth as much as 78% more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Searching For A Fresh Perspective?

The market won’t wait. These fast-moving stocks are hot now. Grab the list before they run:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com